# Aiolos Bio

**Canonical:** https://apis.io/providers/aiolos-bio/  
**Website:** https://aiolosbio.com/  
**APIs profiled:** 0

Aiolos Bio was a clinical-stage biopharmaceutical company founded in 2023 with offices in San Francisco, California and London, United Kingdom, developing treatments for respiratory and inflammatory disease. Its sole disclosed asset was AIO-001, a half-life-extended monoclonal antibody against thymic stromal lymphopoietin (TSLP), positioned as a Phase 2-ready candidate for moderate-to-severe asthma with potential six-month dosing intervals. The company launched in October 2023 with an oversubscribed $245 million Series A co-led by Atlas Venture, Bain Capital Life Sciences, Forbion and Sofinnova Investments, with RA Capital Management. GSK plc agreed to acquire it on 9 January 2024 for $1 billion upfront plus up to $400 million in milestones, completing on 14 February 2024. Aiolos Bio is a drug developer, not a software vendor: it never ran a developer program, public API, SDK or machine-readable contract, and aiolosbio.com now serves a blanket HTTP 301 to www.gsk.com on every path.

## Kin Score — 2.9 / 100 (minimal)

Scored 2026-09-14 under rubric 0.22.0.

| Facet | Score |
|---|---|
| Discoverability | 46.3 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Security (1)

- **Aiolos Bio Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Biotechnology, Biopharmaceutical, Pharmaceuticals, Drug Development, Clinical Trials, Respiratory, Immunology, Monoclonal Antibodies, Life Sciences, Acquired

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/aiolos-bio/). Scores are computed from the provider's own public artifacts under a published rubric.